


New RH5-based malaria prophylaxis with stronger infection inhibition

RH5 is the leading target for blood-stage malaria vaccines. Now, human mAbs have been isolated and studied for the first time, providing strategies for biologics development, vaccine design and seasonal prophylactic use.

Applications: Malaria vaccine design, biologics, antimalarial drug development



Features	Benefits
Identification of neutralising (blue) and non-neutralising (green) mAbs that together bind RH5 to synergistically inhibit merozoite (MZ) invasion of red blood cells (RBC)	Facilitate structure-guided prophylaxis and biologics development to maximize antibody efficacy against blood-stage malaria
Potential of neutralising antibodies by non-neutralising antibodies	Antimalarial antibody combinations that neutralise merozoites with a higher potency than ever before
Uses human antibodies	Better for human drug development than animal-derived antibodies
Multiple, distinct neutralising binding sites identified	Increased targeting to enhance neutralisation

Patented and Available for

- Co-development
- Consulting

- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.